2-(4-chlorobutyl)benzo[d]thiazole | 1037160-88-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-(4-chlorobutyl)benzo[d]thiazole
• 英文别名: 2-(4-Chlorobutyl)-1,3-benzothiazole
• CAS: 1037160-88-5
• 化学式: C₁₁H₁₂ClNS
• 分子量: 225.742
• InChiKey: GZOFPDORZLGANM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-chlorobutyl)benzo[d]thiazole 在 盐酸 、 potassium carbonate 、 potassium iodide 作用下， 以 乙腈 为溶剂， 生成 2-(4-(4-(4-chlorophenyl)piperazin-1-yl)butyl)benzo[d]thiazole dihydrochloride
  参考文献：
  名称：

  Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): A search for new dual-acting agents as potential antidepressants

  摘要：

  The synthesis and evaluation of several benzothiazole-based compounds are described in an attempt to identify novel dual-acting 5HT(1A) receptor and SERT inhibitors as new antidepressants. Binding affinities at the 5HT(1A) receptor and the serotonin transporter do not appear to be congruent and other areas of the binding sites would need to be explored in order to improve binding simultaneously at both sites. Compounds 20 and 23 show moderate binding affinity at the 5HT(1A) receptor and the SERT site and thus, have the potential to be further explored as dual-acting agents. In addition, compound 20 binds with low affinity to the dopamine transporter (DAT), the norepinephrine transporter (NET) and 5HT(2C) receptor, which are desirable properties as selectivity for SERT (and not DAT or NET) is associated with an absence of cardiovascular side effects. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2012.03.042
• 作为产物：
  描述：

  5-氯代戊酰氯 、 2-氨基苯硫醇 以 甲苯 为溶剂， 以66 %的产率得到2-(4-chlorobutyl)benzo[d]thiazole
  参考文献：
  名称：

  苯并噻唑类似物治疗可卡因使用障碍的药理学和治疗潜力

  摘要：

  多巴胺 D 4受体 (D 4 R)（在控制认知、注意力和决策的大脑区域中表达）的药理学靶向可能有助于治疗包括物质使用障碍 (SUD) 在内的多种神经精神疾病。本研究重点是合成和评估一系列新型苯并噻唑类似物，旨在靶向 D 4 R。我们鉴定了几种具有高 D 4 R 结合亲和力 ( K i ≤ 6.9 nM) 且选择性比其他 D 2高 91 倍的化合物。具有多种部分激动剂和拮抗剂特征的类受体（D 2 R、D 3 R）。新型类似物16f是一种强效低效 D 4 R 部分激动剂，在大鼠和人肝微粒体中代谢稳定，并且在大鼠中具有出色的脑渗透性（AUC脑/血浆> 3）。 16f (5–30 mg/kg, ip) 剂量依赖性地减少大鼠静脉内可卡因自我给药，这与 D 4 R 选择性拮抗剂先前产生的结果一致。 5-HT 2A或 5-HT 2B的脱靶拮抗作用也可能导致这些效应。 16f的结果支持在 SUD 治疗中进一步努力以

  DOI：

  10.1021/acs.jmedchem.3c00734

文献信息

• Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors
  作者：Edward Ofori、Xue Y. Zhu、Jagan R. Etukala、Barbara A. Bricker、Seth Y. Ablordeppey

  DOI：10.1016/j.bmc.2016.09.019

  日期：2016.11

  complex and involve multiple receptor systems and thus, the treatment options for these diseases must focus on targeting the multiple receptors implicated in the various disorders. Schizophrenia and depression are examples of such diseases and their pharmacotherapy thus depends on agents which target multiple receptors including the dopamine, serotonin and even cholinergic receptors at the same time. In our

  中枢神经系统疾病通常很复杂，涉及多个受体系统，因此，这些疾病的治疗方案必须集中于针对与各种疾病有关的多个受体。精神分裂症和抑郁症是此类疾病的例子，因此它们的药物治疗取决于同时靶向多种受体的药物，包括多巴胺、血清素甚至胆碱能受体。在我们之前寻找多受体配体的活动中，我们已确定苯并噻唑1a作为初始先导分子。在目前的工作中，我们扩展了1a的结构亲和关系 (SAFIR) ，从而鉴定出部分抑制的丁酰苯3j作为有效且选择性的双 5-HT 1A和 5-HT 7受体配体。预计化合物3j可以作为我们寻找具有治疗 CNS 起源疾病潜力的新型配体的进一步开发的新先导。
• ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS
  申请人：Florida A&M University

  公开号：US20180193330A1

  公开（公告）日：2018-07-12

  Derivatives of 1,2,3,4-tetrahydroisoquinoline (THIQ) having the general formula A-(CH 2 ) n —B are provided, wherein A is THIQ or a substituted derivative thereof and B is an aryl, cycloalkylaryl, or cycloalkyl group, wherein A and B are linked to each other by an alkyl or substituted alkyl chain. The compounds are useful as selective ligands (agonists or antagonists) of central nervous system receptors, and in particular of the seratonin receptors. The compounds or their salts can be formulated into pharmaceutical in need thereof by any route of administration suitable for a desired treatment protocol and especially for the treatment of psychiatric disorders.

  1,2,3,4-四氢异喹啉（THIQ）的衍生物具有一般公式A-(CH2)n—B，其中A是THIQ或其取代衍生物，B是芳基、环烷基芳基或环烷基基团，其中A和B通过烷基或取代烷基链相连。这些化合物可用作中枢神经系统受体的选择性配体（激动剂或拮抗剂），特别是血清素受体的配体。这些化合物或其盐可以通过适合所需治疗方案的任何给药途径制成药物，特别适用于治疗精神障碍。
• Functionalized Orthoesters as Powerful Building Blocks for the Efficient Preparation of Heteroaromatic Bicycles
  作者：Gulluzar Bastug、Christophe Eviolitte、István E. Markó

  DOI：10.1021/ol301472a

  日期：2012.7.6

  By combining substituted anilines with functionalized orthoesters, an efficient and connective methodology for the preparation of benzoxazole, benzothiazole, and benzimidazole derivatives has been established. The versatility of this approach enables the development of new libraries of heterocycles containing multifunctional sites.

  通过将取代的苯胺与官能化的原酸酯组合，已建立了一种高效且结缔的方法，用于制备苯并恶唑，苯并噻唑和苯并咪唑衍生物。这种方法的多功能性使得能够开发包含多功能位点的杂环新库。
• Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores
  作者：Jagan R. Etukala、Xue Y. Zhu、Suresh V.K. Eyunni、Edem K. Onyameh、Edward Ofori、Barbara A. Bricker、Hye J. Kang、Xi-Ping Huang、Bryan L. Roth、Seth Y. Ablordeppey

  DOI：10.1016/j.bmc.2016.06.011

  日期：2016.8

  Several known D-2 pharmacophores have been explored as templates for identifying ligands with multiple binding affinities at dopamine and serotonin receptors considered as clinically relevant receptors in the treatment of neuropsychiatric diseases. This approach has resulted in the identification of ligands that target multiple CNS receptors while avoiding others associated with deleterious effects. In particular, compounds 11, 15 and 22 may have potential for further development as antipsychotic agents as they favorably interact with the clinically relevant receptors including D2R, 5-HT1AR, and 5-HT7R. We have also identified the pair of compounds 11 and 10 as high affinity D2R ligands with and without SERT binding affinities, respectively. These differential binding profiles endow the pair with the potential for evaluating SERT contributions to antipsychotic drug activity in animal behavioral models. In addition, compound 11 has no significant affinity for 5-HT2CR and binds only moderately to the H1R, suggesting it may not induce weight gain or sedation when used clinically. Taken together, compound 11 displays an interesting pharmacological profile that necessitates the evaluation of its functional and in vivo effects in animal models which are currently ongoing. Published by Elsevier Ltd.
• Structure–activity relationship studies of SYA 013, a homopiperazine analog of haloperidol
  作者：Kwakye Peprah、Xue Y. Zhu、Suresh V.K. Eyunni、Jagan R. Etukala、Vincent Setola、Bryan L. Roth、Seth Y. Ablordeppey

  DOI：10.1016/j.bmc.2012.01.022

  日期：2012.3

  Structure-activity relationship studies on 4-(4-(4-chlorophenyl)-1,4-diazepan-1-yl)-1-(4-fluorophenyl) butan-1-one (SYA 013), a homopiperazine analog of haloperidol has resulted in an understanding of the effect of structural modifications on binding affinity at dopamine and serotonin receptor subtypes. Further exploration, using bioisosteric replacement strategies has led to the identification of several new agents including compounds 7, 8, 11 and 12 which satisfy the initial criteria for further exploration as new antipsychotic agents. In addition, compound 18, a D-3 selective tropanol, has been identified as having the potential for further optimization into a useful drug which may combat neuropsychiatric diseases. Published by Elsevier Ltd.